Celgene Earnings Beat Views; Guidance Raised A Bit
Big-cap biotech Celgene early Thursday beat analysts' third-quarter expectations and raised its EPS outlook, though its best-selling drug faced a few head winds. Celgene (CELG) said sales rose 14% over the year-earlier quarter to $1.42 billion, a hair above analysts' consensus of $1.41 billion. Adjusted earnings rose 26% to $1.29 a share, beating consensus by 2 cents. The company's shares, up 10% for the year, rose a fraction Thursday, closing at
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here